StockWatch
·
Filing
Q3

Sterling and Wilson Renewable Energy Ltd

SWSOLARFY2516 Jan 2025
Revenue+78.3%
Net Profit+100.0%
OPM0.05%

P&L

Quarterly Consolidated

Revenue
+78.3%1.8K
Expenditure
+72.5%1.8K
Net Profit
+100.0%17.14
NPM 0.93%EPS ₹0.64+2033.3%

vs Q2 FY25

Sterling and Wilson Renewable Energy Ltd Achieves Second Highest Quarterly Revenue Since Listing

16 Jan 2025 · 16 Jan 2025, 09:26 pm

Summary

Sterling and Wilson Renewable Energy Ltd (SWREL) has announced its results for the third quarter of FY25, achieving its second highest quarterly revenue milestone since going public. The company has experienced a robust YoY revenue growth of 215% and a QoQ growth of 78%. Aided by operational efficiencies, the company has achieved positive operational EBITDA for past three consecutive quarters now, with a PBT of INR 41 crore this quarter. The order inflow momentum continues to remain strong, with INR 5,679 crore in the nine-month period.

Key Highlights

  1. 1

    Consolidated revenues up 215% YoY and 78% QoQ to INR 1,837 crore

  2. 2

    Operational EBIDTA has been positive for three consecutive quarters and grown to ~INR 90 crore in Q3

  3. 3

    PBT has more than doubled sequentially to INR 41 crore

  4. 4

    Net debt declines sequentially by ~INR 150 crore to INR 175 crore

  5. 5

    Order inflow continues to remain strong amounting to INR 5,679 crore in 9MFY25

Management Comments

M

Mr. CK Thakur

CEO - Asia, Africa, LATAM & Europe, Sterling and Wilson Renewable Energy Ltd.

Our performance this quarter brings forth the resilience of our business model. We are significantly scaling up operations and focused on improving profitability. With a steady flow of high-value domestic orders in this quarter and a robust project pipeline across both domestic and international markets, we are poised to capitalize on emerging opportunities. We continue to drive growth, enhance operational excellence and deliver unparalleled value to our stakeholders.

Informational and educational content only. Not investment advice.